BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/13/2026 7:25:29 AM | Browse: 2 | Download: 0
 |
Received |
|
2026-02-13 02:35 |
|
Peer-Review Started |
|
2026-02-13 02:35 |
|
First Decision by Editorial Office Director |
|
2026-03-03 09:30 |
|
Return for Revision |
|
2026-03-03 09:30 |
|
Revised |
|
2026-04-04 13:59 |
|
Publication Fee Transferred |
|
2026-05-01 11:34 |
|
Second Decision by Editor |
|
2026-07-02 02:34 |
 |
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-07-02 08:09 |
|
Articles in Press |
|
2026-07-02 08:09 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-16 10:06 |
|
Publish the Manuscript Online |
|
2026-08-13 07:25 |
| ISSN |
2220-6124 (online) |
| Open Access |
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Clinical Neurology |
| Manuscript Type |
Randomized Controlled Trial |
| Article Title |
Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ashraf Hassan Abd El Mobdy, Hayam Ahmed Hebah, Mohammed Ali Ezzat, Basant Abdelkarim Eid Mohamed and Fatma Abdelrahman Ahmed |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ashraf Hassan Abd El Mobdy, Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, Cairo, Egypt., Ahmed Fakhry Street, Nasr City, Cairo, Egypt, Cairo 31511, Al Qāhirah, Egypt. ashrafnephro@med.asu.edu.eg |
| Key Words |
Pentoxifylline; Inflammatory marker; Non-diabetic; Chronic kidney disease; Tumour necrosis factor-alpha |
| Core Tip |
This randomized controlled study evaluated the effect of pentoxifylline (PTX) on inflammation and disease progression in non-diabetic chronic kidney disease (CKD) stages 3-4. Adding PTX to standard therapy significantly reduced C-reactive protein and proteinuria compared with standard treatment alone. Changes in tumour necrosis factor-alpha were inversely correlated with estimated glomerular filtration rate and urinary protein-to-creatinine ratio, highlighting a link between inflammation and renal function decline. PTX may offer additional anti-inflammatory and renoprotective benefits in non-diabetic CKD. |
| Publish Date |
2026-08-13 07:25 |
| Citation |
Abd El Mobdy AH, Hebah HA, Ezzat MA, Eid Mohamed BA, Ahmed FA. Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label. World J Nephrol 2026; 15(3): 120037
|
| URL |
https://www.wjgnet.com/2220-6124/full/v15/i3/120037.htm |
| DOI |
https://doi.org/10.5527/wjn.120037 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
